U.S. markets closed
  • S&P Futures

    3,754.50
    -2.25 (-0.06%)
     
  • Dow Futures

    29,981.00
    -1.00 (-0.00%)
     
  • Nasdaq Futures

    11,537.75
    -4.00 (-0.03%)
     
  • Russell 2000 Futures

    1,759.30
    +1.20 (+0.07%)
     
  • Crude Oil

    88.36
    -0.09 (-0.10%)
     
  • Gold

    1,718.20
    -2.60 (-0.15%)
     
  • Silver

    20.64
    -0.02 (-0.12%)
     
  • EUR/USD

    0.9798
    +0.0003 (+0.03%)
     
  • 10-Yr Bond

    3.8260
    +0.0670 (+1.78%)
     
  • Vix

    30.52
    +1.97 (+6.90%)
     
  • GBP/USD

    1.1170
    +0.0001 (+0.01%)
     
  • USD/JPY

    145.0410
    -0.0270 (-0.02%)
     
  • BTC-USD

    19,986.51
    -400.16 (-1.96%)
     
  • CMC Crypto 200

    454.54
    -8.59 (-1.85%)
     
  • FTSE 100

    6,997.27
    -55.35 (-0.78%)
     
  • Nikkei 225

    27,175.25
    -136.05 (-0.50%)
     

Teladoc (TDOC) Outpaces Stock Market Gains: What You Should Know

·2 min read

Teladoc (TDOC) closed the most recent trading day at $31.67, moving +1.15% from the previous trading session. This change outpaced the S&P 500's 0.34% gain on the day. At the same time, the Dow added 0.1%, and the tech-heavy Nasdaq gained 0.02%.

Coming into today, shares of the telehealth services provider had lost 20.63% in the past month. In that same time, the Medical sector lost 5.59%, while the S&P 500 lost 7.95%.

Wall Street will be looking for positivity from Teladoc as it approaches its next earnings report date. The company is expected to report EPS of -$0.59, down 11.32% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $608.35 million, up 16.62% from the prior-year quarter.

For the full year, our Zacks Consensus Estimates are projecting earnings of -$61.39 per share and revenue of $2.4 billion, which would represent changes of -4515.79% and +18.08%, respectively, from the prior year.

Investors should also note any recent changes to analyst estimates for Teladoc. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.

Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 6.33% higher. Teladoc is currently sporting a Zacks Rank of #3 (Hold).

The Medical Services industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 151, which puts it in the bottom 41% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Teladoc Health, Inc. (TDOC) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research